Tevimbra is under clinical development by BeiGene and currently in Phase II for Marginal Zone B-cell Lymphoma.

Research shows routine follow-up misses most relapses in lymphoma patients in remission, highlighting the need for improved ...

"Imugene doses first Australian subject in trial of B-cell lymphoma drug candidate" was originally created and published by ...

XYF-19 is under clinical development by Xi'An Yufan Biotechnology and currently in Phase I for Diffuse Large B-Cell Lymphoma.

A recent retrospective study has shed new light on the effectiveness of chimeric antigen receptor T cell therapy for patients ...

Dr John Leonard shares key updates on DLBCL at ASH 2024, including long-term POLARIX trial data, ctDNA insights, and real-world results for polatuzumab, liso-cel, and bispecifics after CAR-T failure.

The real-world effectiveness of Monjuvi for relapsed or refractory diffuse large B-cell lymphoma in the U.S. was demonstrated ...

Stage 4 diffuse large B-cell lymphoma (DLBCL) is a rapidly growing lymphoma affecting at least one other organ outside the lymphatic system. Cancer is the unusual growth and spread of cells within ...

Navi Mumbai: In a medical breakthrough at Kokilaben Dhirubhai Ambani Hospital, Navi Mumbai, a 39-year-old Rijesh Nair, a ...

Diffuse large B-cell lymphoma, which accounts for nearly half of all non-Hodgkin lymphoma (NHL) cases, is particularly aggressive and presents significant challenges for both patients and ...

As we start the New Year, it’s time to schedule your annual wellness visit. This important appointment is to talk about any ...